You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

ALLERGAN Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ALLERGAN, and what generic alternatives to ALLERGAN drugs are available?

ALLERGAN has seventy-two approved drugs.

There are two US patents protecting ALLERGAN drugs.

Summary for ALLERGAN

US Patents:	2
Tradenames:	69
Ingredients:	53
NDAs:	72
Patent Litigation for ALLERGAN:	See patent lawsuits for ALLERGAN
PTAB Cases with ALLERGAN as patent owner:	See PTAB cases with ALLERGAN as patent owner

Drugs and US Patents for ALLERGAN

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	THYROLAR-3	liotrix (t4;t3)	TABLET;ORAL	016807-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Allergan	BREVICON 21-DAY	ethinyl estradiol; norethindrone	TABLET;ORAL-21	017566-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Allergan	ETHAMIDE	ethoxzolamide	TABLET;ORAL	016144-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Allergan Herbert	EXSEL	selenium sulfide	LOTION/SHAMPOO;TOPICAL	083892-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Allergan	KADIAN	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	020616-006	Oct 27, 2006		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ALLERGAN

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	GELNIQUE 3%	oxybutynin	GEL, METERED;TRANSDERMAL	202513-001	Dec 7, 2011	8,241,662	⤷ Sign Up
Allergan	TAZORAC	tazarotene	CREAM;TOPICAL	021184-002	Sep 29, 2000	5,089,509	⤷ Sign Up
Allergan	NAMENDA	memantine hydrochloride	SOLUTION;ORAL	021627-001	Apr 18, 2005	5,061,703*PED	⤷ Sign Up
Allergan	GELNIQUE 3%	oxybutynin	GEL, METERED;TRANSDERMAL	202513-001	Dec 7, 2011	7,179,483	⤷ Sign Up
Allergan	ZYMAR	gatifloxacin	SOLUTION/DROPS;OPHTHALMIC	021493-001	Mar 28, 2003	6,333,045*PED	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for ALLERGAN drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Capsules	60 mg	➤ Subscribe	2009-03-02
➤ Subscribe	Transdermal System Extended-re	3.9 mg/24 hrs	➤ Subscribe	2008-08-19
➤ Subscribe	Ophthalmic Solution	0.30%	➤ Subscribe	2007-07-19
➤ Subscribe	Tablets	2.5 mg, 5 mg, 10 mg, and 20 mg	➤ Subscribe	2011-12-19
➤ Subscribe	Sublingual Tablets	2.5 mg	➤ Subscribe	2017-07-27
➤ Subscribe	Capsules	4 mg and 8 mg	➤ Subscribe	2012-10-09
➤ Subscribe	Ophthalmic Solution	0.05%	➤ Subscribe	2008-10-14
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Sublingual Tablets	5 mg and 10 mg	➤ Subscribe	2013-08-13

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.